Faculty of Life Sciences, University of Manchester, AV Hill Building, Manchester M13 9PT, UK.
Biochem Soc Trans. 2011 Aug;39(4):886-90. doi: 10.1042/BST0390886.
Inflammation has long been proposed as having a role in AD (Alzheimer's disease), although it remains unclear whether inflammation represents a cause or consequence of AD. Evidence from the clinical setting in support of a role for inflammation in AD includes increased expression of inflammatory mediators and microglial activation in the post-mortem AD brain. Also, epidemiological studies on AD patients under long-term treatment with non-steroidal anti-inflammatory drugs suggest some benefits, although recent prospective trials showed no effect. Furthermore, in AD patients, infection and other systemic inflammatory events worsen symptoms. Finally, several inflammatory genes are associated with increased risk of AD. Therefore, to elucidate the underlying mechanisms of AD and the role of inflammation, researchers have turned to experimental models and here we present a short overview of some key findings from these studies. Activation of microglia is seen in various transgenic models of AD, with both a protective role and a detrimental role being ascribed to it. Early microglial activation is probably beneficial in AD, through phagocytosis of amyloid β-peptide. At later stages however, pro-inflammatory cytokine release from microglia could contribute to neuronal demise. A better understanding of microglial phenotype at the various stages of AD is therefore still required. Although most studies suggest a detrimental role for pro-inflammatory cytokines such as interleukin-1 and tumour necrosis factor in AD, contradictory findings do exist. Age-related and differential cellular expression of these inflammatory mediators is probably a key determinant of their exact contribution to AD. In conclusion, there is no doubt that inflammatory processes are part of the pathophysiology of AD, but a better understanding of the exact contribution at different stages of the disease process is still required before appropriate treatment strategies can be devised.
炎症长期以来被认为与 AD(阿尔茨海默病)有关,尽管炎症是 AD 的病因还是结果仍不清楚。来自临床研究的证据支持炎症在 AD 中的作用,包括 AD 患者死后大脑中炎症介质表达增加和小胶质细胞激活。此外,对长期接受非甾体抗炎药治疗的 AD 患者进行的流行病学研究表明存在一些益处,但最近的前瞻性试验没有显示出效果。此外,在 AD 患者中,感染和其他全身炎症事件会使症状恶化。最后,一些炎症基因与 AD 风险增加相关。因此,为了阐明 AD 的潜在机制和炎症的作用,研究人员转向了实验模型,在这里我们简要概述了这些研究中的一些关键发现。AD 的各种转基因模型中均可见小胶质细胞激活,它具有保护作用和有害作用。早期小胶质细胞激活可能通过吞噬淀粉样β肽对 AD 有益。然而,在后期,小胶质细胞中促炎细胞因子的释放可能导致神经元死亡。因此,仍然需要更好地了解 AD 各个阶段的小胶质细胞表型。尽管大多数研究表明促炎细胞因子如白细胞介素-1 和肿瘤坏死因子在 AD 中具有有害作用,但也存在矛盾的发现。这些炎症介质的年龄相关性和细胞差异表达可能是其对 AD 确切贡献的关键决定因素。总之,毫无疑问,炎症过程是 AD 病理生理学的一部分,但在制定适当的治疗策略之前,仍需要更好地了解疾病过程不同阶段的确切贡献。